JAK Inhibition in Ulcerative Colitis

Status Recruiting

Clinical Trial Summary

The treatment for Ulcerative Colitis (UC) aims to achieve and maintain remission and is usually lifelong and expensive. Current available medications are unable to break the cycle of chronic inflammation, and still a significant proportion of patients will fail to respond (primary non-response) or lose response over time (secondary non-response). There is now growing evidence that there is substantial interpatient variation in the composition of the inflammation associated network of immune cells. A deeper knowledge of the patient's alterations in the mucosal immune response would help identify key drivers of inflammation and select the appropriate therapy. By analyzing the changes in the composition of immune cells induced by Janus Kinase (JAK) inhibition, we aim to obtain a better insight into the mechanistic effects of JAK inhibition and the downstream effects. These mechanistic insights are needed to identifying potential responders and non-responders in the future.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05456412
Study type	Interventional
Source	Leiden University Medical Center
Contact	Philip W Voorneveld, MD, PhD
Phone	+31715296370
Email	p.w.voorneveld@lumc.nl
Status	Recruiting
Phase	N/A
Start date	December 20, 2022
Completion date	September 2026

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04989907` - A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
Completed	`NCT03494764` - Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares	Phase 2
Recruiting	`NCT03937609` - TITRATE (inducTIon for acuTe ulceRATivE Colitis)	Phase 4
Completed	`NCT00503243` - Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis	Phase 3
Completed	`NCT03606499` - Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
Completed	`NCT02537210` - Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis	N/A
Active, not recruiting	`NCT02316678` - Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics	N/A
Completed	`NCT00488631` - An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 3
Completed	`NCT00928681` - A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis	Phase 1
Recruiting	`NCT05242484` - A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 2
Completed	`NCT01036022` - Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis	Phase 2
Recruiting	`NCT03841045` - Unraveling a Potential Connection Between Bilirubin Metabolism, Gut Microbiota and Inflammatory Bowel Diseases
Active, not recruiting	`NCT05528510` - A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 3
Completed	`NCT02825914` - CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)	N/A
Recruiting	`NCT06049017` - A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis	Phase 2
Completed	`NCT04567628` - Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes
Withdrawn	`NCT05999708` - A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants	Phase 1
Recruiting	`NCT05611671` - A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC	Phase 2
Active, not recruiting	`NCT03596645` - A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis	Phase 3
Completed	`NCT03648541` - BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis	Phase 2